Transamerica Financial Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Transamerica Financial Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-9,375	Closed	-$664K	–	899
2015 Q2	$664K	Buy	9,375 +4,762	+103%	+$343K	0.05%	205
2015 Q1	$325K	Buy	+4,613	New	+$313K	0.02%	281

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

AHS

Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Transamerica Financial Advisors's PPH Position: Q3 2015 in Review

Transamerica Financial Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2015, closing a stake of 9,375 shares — an estimated $664K sold.

Transamerica Financial Advisors first reported a position in PPH in Q1 2015 and held it in 2 quarters. The position peaked at $664K in Q2 2015. 60 funds tracked by Wall St. Rank hold PPH as of Q3 2015.

Transamerica Financial Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q3 2015 after selling out during the quarter.
Transamerica Financial Advisors sold 9,375 VanEck Pharmaceutical ETF shares in Q3 2015, an estimated $664K.
Transamerica Financial Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2015 and held it in 2 quarters.
Transamerica Financial Advisors's VanEck Pharmaceutical ETF position peaked at $664K in Q2 2015.
60 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2015.

Based on Transamerica Financial Advisors's 13F filing for Q3 2015, filed 20 Oct 2015.